Case study matrix3-pdf.xls

A-D Nutraceuticals -- Case Study Matrix Notes
All patients entering therapy were diagnosed as terminal or at the end of Stage IV. Only patients surviving longer than ninety days from beginning of MSQ treatment have been included in the matrix.
Virtually all patients had preexisting or extenuating conditions. Most were unable to continue with additional interventions due to: * Chemotherapy - toxicity limits or patient could not tolerate severe side effects. * Radiation - maximum exposure limits reached without a viable resolution. * Surgery - and/or additional surgery no longer a viable option.
The formulaic progression of the MSQ therapy began in 2000 with #11, and has progressed to #15F in 2008 as the latest compounded formulation. Efficacy and effectiveness have been noted as a result in newer formulations.
Patients were self administered at home and responsible for their own dosages and scheduling times. Clinical oversight and consistent documentation will be a focus in future trials as a quality control. The minimum base MSQ therapy for Stage I-II patients requires consumption of two quarts over a twenty one day period. Terminal patients generally require at least two full courses to achieve remission status.
In conclusion, patients not achieving remission were often too far advanced, overriding complications, or their immune system was too Contact: Website -adnutraceuticals.com E-mail - info@adnutraceuticals.com A-D Nutraceuticals -- Case Study Summary Matrix
Dosage Therapy Therapy
Remission
Prognosis Treatment Radiology
Preexisting Conditions Patient Therapy Notes
Inoperable Squamos cell Many complications from carcinoma, pleuritis, enlarged heart, obesity, terminal cancer, heavy diabetes, liver problems smoker and drinker, 12/2000 regression > surgery, vaginal and 2) #11A 2) #11A 50% of cervical bowel fistulas. 8/01 brain abscess, 1/02 tolerate half doses of revealed > 25 soft tissue late 2/03 all CBC, blast Transpupillar diode laser Outcome unknown, thermotherapy on three tumor progression was A-D Nutraceuticals -- Case Study Summary Matrix
Dosage Therapy Therapy
Remission
Prognosis Treatment Radiology
Preexisting Conditions Patient Therapy Notes
withdrawal from therapy. progression and occlusion surgery 1993, stroke. Unable to Stability and lymphadenectomy, 2000 problems w/in 2 weeks, resection, 5/2001 tumor work one month later. quadrant resection and weeks resolution of lymphadenectomy, 3/04 dyspnea and bone pain, CT - multiple mets in bone mets, 5/04 & 8/04 left side pleural fluid CT's lung mets, pleural regressed completely, fluid and dyspnea, w/ A-D Nutraceuticals -- Case Study Summary Matrix
Dosage Therapy Therapy
Remission
Prognosis Treatment Radiology
Preexisting Conditions Patient Therapy Notes
and transrectal biopsy to rapid decline of PSA drain abscess, 8/28/03 prostastectomy and cyst drainage. Cyst resolved by 1/04. A 3/04 PSA - (.46ng/ml) & 7/04 PSA (23ng/ml) suggested recurrence.
enlarged prostrate, PSA therapy, reported overall (9.5 nag/ml). adenocarcinoma. Whole normal range, and other mets to skull, scapula and spinal vertebrae.
A-D Nutraceuticals -- Case Study Summary Matrix
Dosage Therapy Therapy
Remission
Prognosis Treatment Radiology
Preexisting Conditions Patient Therapy Notes
lympadenectomy, 2002 much improved, decr. uterectomy and adnexal alkaline phosphotase removal (reprod. sternum radiation, 6/04 decrease in bone pain. lessened bone clavicle and sternum. CT 6/1/05 Resumed MSQ pain, mets too showed sub pleural mets 14A, bone pain reduction 6/05 scan showed mets help w/ bone pain, on entire spine. 1/05 since 1999. 6/04 Leuk. high WBC 608 G/L. crisis reversal, & COP therapy. High blood stabilized, steroids failed. Also had 43.5 G/L resulted in continue longer disease w/ diarrhea that blood counts and overall continue long term therapy due to bowel disease and chronic diarrhea.
A-D Nutraceuticals -- Case Study Summary Matrix
Dosage Therapy Therapy
Remission
Prognosis Treatment Radiology
Preexisting Conditions Patient Therapy Notes
Massive metastatic liver Substantially improved. and 12/06. Chemo follow tissue and histological up. CT-Pet scan 9/07 Patient refused chemo, scan 3/08 showed no took MSQ, a third sched. tumors or abnormal resection on 12/07 found lymph nodes.
no tumors from 9/07 CT scan.
2/07 Pruritis and mult. drug allergies, elevated months. 6/07 Liver test liver enzymes, 3/07 infiltration. Gall bladder variable through 8/08 removed, tumor was non-due to infection. 7/08 present. 17 months later, patient is stable and therapy continues.

Source: http://adnutraceuticals.com/docs/casematrix.pdf